For help on how to get the results you want, see our search tips.
208 results
Categories
Human Remove Human filter
-
List item
Summary of opinion: Steglatro
ertugliflozin, opinion date: 16/09/2021, Positive, Last updated: 30/09/2021 -
List item
Summary of opinion: Trelegy Ellipta
fluticasone furoate, umeclidinium, vilanterol, opinion date: 25/02/2021, Negative, Last updated: 26/02/2021 -
List item
Summary of opinion: Elebrato Ellipta
fluticasone furoate, umeclidinium, vilanterol, opinion date: 25/02/2021, Negative, Last updated: 26/02/2021 -
List item
Summary of opinion: Temybric Ellipta
fluticasone furoate, umeclidinium, vilanterol, opinion date: 25/02/2021, Negative, Last updated: 26/02/2021 -
List item
Summary of opinion: Sondelbay
teriparatide, opinion date: 27/01/2022, Positive, Last updated: 28/01/2022 -
List item
Summary of opinion: Senshio
ospemifene, opinion date: 27/01/2022, Positive, Last updated: 28/01/2022 -
List item
Summary of opinion: Segluromet
ertugliflozin, metformin hydrochloride, opinion date: 16/09/2021, Positive, Last updated: 17/09/2021 -
List item
Summary of opinion: Carvykti
ciltacabtagene autoleucel, opinion date: 24/03/2022, Positive, Last updated: 25/03/2022 -
List item
Summary of opinion: Polivy
polatuzumab vedotin, opinion date: 24/03/2022, Positive, Last updated: 25/03/2022 -
List item
Summary of opinion: Beovu
brolucizumab, opinion date: 24/02/2022, Positive, Last updated: 25/02/2022 -
List item
Summary of opinion: Lunsumio
mosunetuzumab, opinion date: 22/04/2022, Positive, Last updated: 22/04/2022 -
List item
Summary of opinion: Yescarta
axicabtagene ciloleucel, opinion date: 22/04/2022, Positive, Last updated: 22/04/2022 -
List item
Summary of opinion: Retsevmo
selpercatinib, opinion date: 22/04/2022, Positive, Last updated: 22/04/2022 -
List item
Summary of opinion: Keytruda
pembrolizumab, opinion date: 22/04/2022, Positive, Last updated: 22/04/2022 -
List item
Summary of opinion: Kinpeygo (new)
budesonide, opinion date: 19/05/2022, Positive, Last updated: 20/05/2022 -
List item
Summary of opinion: Xeljanz (new)
tofacitinib, opinion date: 19/05/2022, Positive, Last updated: 20/05/2022 -
List item
Summary of opinion: Nexpovio (new)
selinexor, opinion date: 19/05/2022, Positive, Last updated: 20/05/2022 -
List item
Summary of opinion: Tuznue (new)
trastuzumab, opinion date: 19/05/2022, Negative, Last updated: 20/05/2022 -
List item
Summary of opinion: Hervelous (new)
trastuzumab, opinion date: 19/05/2022, Negative, Last updated: 20/05/2022 -
List item
Summary of opinion: Keytruda (new)
pembrolizumab, opinion date: 19/05/2022, Positive, Last updated: 20/05/2022 -
List item
Summary of opinion: Rinvoq (new)
upadacitinib, opinion date: 19/05/2022, Positive, Last updated: 20/05/2022 -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Kevzara, sarilumab (updated)
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Immunology-Rheumatology-Transplantation
PIP number: EMEA-001045-PIP01-10-M02, Route(s) of administration: Subcutaneous use, Pharmaceutical form(s): Solution for injection
Decision date: 17/03/2021, Last updated: 06/05/2022, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Ultomiris, ravulizumab (updated)
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Haematology-Hemostaseology; Uro-nephrology
PIP number: EMEA-002077-PIP01-16-M04, Route(s) of administration: Intravenous use, Subcutaneous use, Pharmaceutical form(s): Concentrate for solution for infusion, Solution for injection
Decision date: 17/06/2021, Last updated: 28/04/2022, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Venclyxto, Venetoclax (updated)
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Haematology-Hemostaseology; Oncology
PIP number: EMEA-002018-PIP02-16-M04, Route(s) of administration: Oral use, Pharmaceutical form(s): Film-coated tablet, Tablet for oral suspension
Decision date: 09/06/2021, Last updated: 28/04/2022, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Ultomiris, ravulizumab (updated)
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Haematology-Hemostaseology; Uro-nephrology
PIP number: EMEA-001943-PIP01-16-M06, Route(s) of administration: Intravenous use, Subcutaneous use, Pharmaceutical form(s): Concentrate for solution for infusion, Solution for injection
Decision date: 17/06/2021, Last updated: 28/04/2022, Compliance check: X